Vaccines are usually given before illness. Moderna and Merck are testing a different idea: build a vaccine from a tumour after cancer appears, then help the immune system hunt cells carrying its mutations.
On August 19, 2026, the companies said intismeran autogene, also known as V940 or mRNA-4157, met the main goal of the Phase 3 INTerpath-001 melanoma trial when combined with Keytruda, or pembrolizumab. Moderna’s official Phase 3 update calls it a major milestone for personalised mRNA cancer vaccines, but the treatment remains investigational and is not yet approved.
What Exactly Did The Phase 3 Melanoma Trial Show?
INTerpath-001 enrolled 1,137 patients whose stage IIB to IV cutaneous melanoma had been completely removed by surgery. Participants were randomly assigned in a 2:1 ratio to receive intismeran plus Keytruda or Keytruda alone for roughly one year. SEER estimates 112,000 new U.S. melanoma cases and 8,510 deaths in 2026.
At a planned interim analysis, the combination produced statistically significant and clinically meaningful improvements in recurrence-free survival, meaning patients stayed free of cancer recurrence longer. It also improved distant metastasis-free survival, measuring the period before cancer returns at a distant site.
There is one important caution. Moderna and Merck have not yet released the full Phase 3 numbers. The 49% reduction in recurrence or death and 59% reduction in distant metastasis or death circulating in reports came from the smaller five-year Phase 2b melanoma study, not from this new Phase 3 readout.
The market reacted sharply too. Moderna shares more than doubled after the announcement, while Merck also rose.
How Does A Personalised mRNA Cancer Vaccine Work?
Intismeran is not pulled from a shelf and given identically to every patient. It is designed from the genetic features of a person’s tumour. Moderna says each therapy can encode as many as 34 tumour-specific neoantigens, abnormal markers created by cancer mutations.
The process, in simplified form, looks like this:
- A sample of the removed tumour is genetically sequenced.
- Researchers identify mutations that may produce useful neoantigens.
- A patient-specific mRNA sequence is designed around selected targets.
- That mRNA is manufactured as an individualised therapy.
- After injection, immune cells learn to recognise those targets and attack matching cancer cells.
This is why the word “personalised” is central. Two patients with melanoma may receive different mRNA instructions because their tumours carry different mutations.
Why Keytruda Is Paired With The Vaccine
Keytruda is an anti-PD-1 checkpoint inhibitor. It removes one of the brakes that cancer can use to weaken T-cell activity. Intismeran aims to show T cells what to target, while Keytruda helps those immune cells stay active enough to attack.
After surgery, microscopic cancer cells may remain even when visible melanoma is removed. The combination is being tested as adjuvant therapy to reduce recurrence risk.
How Is This Different From A Vaccine That Prevents Disease?
The difference is timing, target, and purpose. Preventive vaccines are normally given before disease develops. They teach the immune system to recognise a pathogen so an infection can be blocked or made less severe.
Cancer prevention vaccines can also work indirectly. According to the National Cancer Institute’s cancer vaccine guidance, treatment vaccines are used in people who already have cancer. By contrast, HPV vaccination blocks infections linked to several cancers, while hepatitis B vaccination reduces infections that can later cause liver cancer.
Intismeran does something else. It is a therapeutic cancer vaccine intended for someone who has already developed melanoma. Rather than targeting a virus, it targets neoantigens generated by mutations inside that person’s tumour.
That distinction also separates it from routine infectious-disease mRNA vaccines. COVID-19 mRNA vaccines deliver instructions for a viral antigen shared across recipients. Intismeran uses mRNA as a delivery platform, but its encoded targets are selected separately for each patient.
What Happens Next For Intismeran And Other mRNA Cancer Vaccines?
The Phase 3 result is not an approval. Moderna and Merck plan to present detailed findings at an international medical meeting and discuss regulatory filings. Overall survival remains one of the trial’s important secondary outcomes, so longer follow-up will matter.
The programme has also moved beyond melanoma. Moderna and Merck have nine Phase 2 and Phase 3 studies under way across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. A Phase 3 study is also testing intismeran as monotherapy and with Keytruda in high-risk stage I non-small cell lung cancer.
For melanoma, the milestone is significant because this is the first positive Phase 3 result reported for an individualised neoantigen therapy and an mRNA-based cancer treatment. It does not prove that personalised vaccines will work across cancers, but it gives the field its strongest late-stage evidence so far.
FAQS
Is intismeran already approved for melanoma?
No. It remains investigational while Moderna and Merck prepare detailed data and discuss regulatory submissions.
Does the vaccine prevent people from developing melanoma?
No. It is designed to treat patients after melanoma develops and has been surgically removed.
How is each personalised vaccine made?
Tumour mutations are sequenced, selected neoantigens are identified, and patient-specific mRNA instructions are manufactured individually.
Why is Keytruda used with intismeran?
Keytruda releases immune-system brakes, while intismeran teaches T cells which tumour-specific targets they should attack.
When could patients receive this treatment routinely?
Routine use depends on full Phase 3 data, regulatory review, approval, manufacturing capacity and availability.
